Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes

Published:2009-02-10 Issue:4 Volume:16 Page:301-306
ISSN:1340-6868
Container-title:Breast Cancer
language:en
Short-container-title:Breast Cancer

Author:

Tanabe Masahiko,Ito Yoshinori,Tokudome Nahomi,Sugihara Tsutomu,Miura Hiroyoshi,Takahashi Shunji,Seto Yasuyuki,Iwase Takuji,Hatake Kiyohiko

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12282-009-0093-0.pdf

Reference22 articles.

1. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol. 1998;16:3439–60.

2. Paterson AHG, Szafran O, Cornish F, Lees AW, Hanson J. Effect of chemotherapy on survival in metastatic breast cancer. Breast Cancer Res Treat. 1981;1:357–63.

3. A’ Hern RP, Smith IE, Ebbs SR. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper-type regimens. Br J Cancer. 1993;67:801–5.

4. Bignazoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer. The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase Trial. J Clin Oncol. 2002;20:3114–21.

5. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003;21:588–92.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innovative lanthanide complexes: Shaping the future of cancer/ tumor chemotherapy;Journal of Trace Elements in Medicine and Biology;2023-12

2. Polypharmacology in Clinical Applications—Anticancer Polypharmacology;Polypharmacology;2022

3. The Design and Application of Nanomaterials as Drug Carriers in Cancer Treatment;Current Medicinal Chemistry;2020-11-04

4. Insights of Nanophytomedicines as a Combinatorial Therapy in Disease Diagnosis and Treatment;Nanophytomedicine;2020

5. Limitations and Opportunities in Topical Drug Delivery: Interaction Between Silica Nanoparticles and Skin Barrier;Current Pharmaceutical Design;2019-06-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3